The effects of the subconjunctival injection of bevacizumab (Avastin) on angiogenesis in the rat cornea

The purpose of this study was to evaluate the effects of the use of the subconjunctival injection of bevacizumab (Avastin) on angiogenesis in the rat cornea. Corneas of 20 Wistar male rats were cauterized with silver nitrate crystal. Animals were divided in four groups: control group (GC) that recei...

Full description

Saved in:
Bibliographic Details
Published in:Anais da Academia Brasileira de Ciências 2007-09, Vol.79 (3), p.389-394
Main Authors: Barros, Luiz F M, Belfort, Jr, Rubens
Format: Article
Language:English
Subjects:
angiogenesis
Angiogenesis Inhibitors - therapeutic use
angiogênese
Animals
Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Humanized
Bevacizumab
cornea
Corneal Neovascularization - chemically induced
Corneal Neovascularization - drug therapy
Corneal Neovascularization - pathology
córnea
Disease Models, Animal
Drug Evaluation, Preclinical
Male
MULTIDISCIPLINARY SCIENCES
neovascularization
neovascularização
Rats
Rats, Wistar
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The purpose of this study was to evaluate the effects of the use of the subconjunctival injection of bevacizumab (Avastin) on angiogenesis in the rat cornea. Corneas of 20 Wistar male rats were cauterized with silver nitrate crystal. Animals were divided in four groups: control group (GC) that received subconjunctivally 0.02 ml of 0.9% saline solution on the day of the lesion; group GO that received subconjunctivally 0.02 ml of bevacizumab just after the lesion; group G3 that received bevacizumab on day 3 and group G5 that received bevacizumab on day 5 after lesion. Animals were euthanized on day 7. The newly formed vessels were quantified after China Ink perfusion and photographs were obtained and analyzed in a computerized system (Image Pro-Plus(R)). In the control group, neovascularization covered 53.56% +/- 15.11 (mean +/- SD) of the corneal surface, compared with 35.57% +/- 18.80 (mean +/- SD) in the G0 group, 30.60%+/-11.82 (mean+/-SD) in the G3 and 35.86%+/-0.07 (mean+/-SD) in the G5. The results showed an inhibition of angiogenesis when the control group was compared with all treated groups. These results suggest that subconjunctival injection of bevacizumab is able to inhibit corneal angiogenesis independently of the day of treatment.
ISSN:0001-3765
1678-2690
0001-3765
1678-2690
DOI:10.1590/s0001-37652007000300004